000128270 001__ 128270
000128270 005__ 20240303002934.0
000128270 0247_ $$2pmid$$apmid:24921086
000128270 0247_ $$2ISSN$$a0020-7136
000128270 0247_ $$2ISSN$$a1097-0215
000128270 0247_ $$2altmetric$$aaltmetric:54828402
000128270 037__ $$aDKFZ-2017-04287
000128270 041__ $$aeng
000128270 082__ $$a610
000128270 1001_ $$0P:(DE-He78)5e6f79f3c71682d052bc2536749ca077$$aSchmeiser, Heinz$$b0$$eFirst author$$udkfz
000128270 245__ $$aExceptionally long-term persistence of DNA adducts formed by carcinogenic aristolochic acid I in renal tissue from patients with aristolochic acid nephropathy.
000128270 260__ $$aBognor Regis$$bWiley-Liss$$c2014
000128270 3367_ $$2DRIVER$$aarticle
000128270 3367_ $$2DataCite$$aOutput Types/Journal article
000128270 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1532335963_25865
000128270 3367_ $$2BibTeX$$aARTICLE
000128270 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000128270 3367_ $$00$$2EndNote$$aJournal Article
000128270 520__ $$aAristolochic acid (AA) causes aristolochic acid nephropathy (AAN), first described in women in Belgium accidently prescribed Aristolochia fangchi in a slimming treatment, and also Balkan endemic nephropathy (BEN), through probable dietary contamination with Aristolochia clematitis seeds. Both nephropathies have a high risk of urothelial cancer, with AA being the causative agent. In tissues of AAN and BEN patients, a distinct DNA adduct, 7-(deoxyadenosin-N6-yl)-aristolactam I (dA-AAI), has been detected. DNA adducts can be removed through DNA repair, they can result in mutations through erroneous DNA replication or they can cause cell death. The dA-AAI adduct induces AT to TA transversions in the tumor-suppressor TP53 gene in experimental systems, matching TP53 mutations observed in urothelial tumors from AAN cancer cases. Using thin-layer chromatography 32P-postlabeling and mass spectrometric analysis we report the detection of dA-AAI in renal DNA from 11 Belgian AAN patients over 20 years after exposure to AA had ceased. Our results showed that dA-AAI is an established biomarker of AA exposure, and that this biomarker can be demonstrated to be persistent decades after a distinct AA exposure. Further, the persistence of dA-AAI adducts appears to be a critical determinant for the AA mutational fingerprint frequently found in oncogenes and tumor suppressor genes recently identified by whole genome sequencing of AA-associated urothelial tumors. The potential for exposure to AA worldwide is high; the unprecedented long-term persistence of dA-AAI provides a useful long-term biomarker of exposure and attests to the role of AA in human urothelial malignancy.
000128270 536__ $$0G:(DE-HGF)POF3-313$$a313 - Cancer risk factors and prevention (POF3-313)$$cPOF3-313$$fPOF III$$x0
000128270 588__ $$aDataset connected to PubMed,
000128270 650_7 $$2NLM Chemicals$$aAristolochic Acids
000128270 650_7 $$2NLM Chemicals$$aBiomarkers
000128270 650_7 $$2NLM Chemicals$$aDNA Adducts
000128270 650_7 $$2NLM Chemicals$$aMutagens
000128270 650_7 $$094218WFP5T$$2NLM Chemicals$$aaristolochic acid I
000128270 7001_ $$aNortier, Jöelle L$$b1
000128270 7001_ $$aSingh, Rajinder$$b2
000128270 7001_ $$aGamboa da Costa, Gonçalo$$b3
000128270 7001_ $$aSennesael, Jacques$$b4
000128270 7001_ $$aCassuto-Viguier, Elisabeth$$b5
000128270 7001_ $$aAmbrosetti, Damien$$b6
000128270 7001_ $$aRorive, Sandrine$$b7
000128270 7001_ $$aPozdzik, Agnieszka$$b8
000128270 7001_ $$aPhillips, David H$$b9
000128270 7001_ $$aStiborova, Marie$$b10
000128270 7001_ $$aArlt, Volker M$$b11
000128270 773__ $$0PERI:(DE-600)1474822-8$$gVol. 135, no. 2$$n2$$p502-507$$tInternational journal of cancer$$v135$$x0020-7136$$y2014
000128270 909CO $$ooai:inrepo02.dkfz.de:128270$$pVDB
000128270 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)5e6f79f3c71682d052bc2536749ca077$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000128270 9131_ $$0G:(DE-HGF)POF3-313$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vCancer risk factors and prevention$$x0
000128270 9141_ $$y2014
000128270 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz
000128270 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000128270 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000128270 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000128270 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bINT J CANCER : 2015
000128270 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bThomson Reuters Master Journal List
000128270 915__ $$0StatID:(DE-HGF)0110$$2StatID$$aWoS$$bScience Citation Index
000128270 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000128270 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000128270 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences
000128270 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews
000128270 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bINT J CANCER : 2015
000128270 9201_ $$0I:(DE-He78)C016-20160331$$kC016$$lGenetische Veränderungen bei der Karzinogenese$$x0
000128270 9201_ $$0I:(DE-He78)E030-20160331$$kE030$$lRadiopharmazeutische Chemie$$x1
000128270 980__ $$ajournal
000128270 980__ $$aVDB
000128270 980__ $$aI:(DE-He78)C016-20160331
000128270 980__ $$aI:(DE-He78)E030-20160331
000128270 980__ $$aUNRESTRICTED